Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the comparative bioavailability of three capsule formulations of MK-0974.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Active Comparator | MK-0974 12MoRT |
|
| 2 | Active Comparator | MK-0974 5Mo5C |
|
| 3 | Active Comparator | MK-0974 12Mo5C |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| telcagepant potassium | Drug | [INTERVENTION NAME: MK-0974 12MoRT] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods |
| Measure | Description | Time Frame |
|---|---|---|
| Area under the curve (AUC(0 to infinity) following single dose administration of MK-0974 12Mo5C and 5Mo5C formulations | Through 48 hours postdose | |
| Peak plasma concentration (Cmax) following single dose administration of MK-0974 12Mo5C and 5Mo5C formulations | Through 48 hours postdose |
| Measure | Description | Time Frame |
|---|---|---|
| Area under the curve (AUC(0 to infinity) following single dose administration of MK-0974 12MoRT and 5Mo5C formulations | Through 48 hours postdose | |
| Peak plasma concentration (Cmax) following single dose administration of MK-0974 12MoRT and 5Mo5C formulations |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| MK-0974 5Mo5C | Drug | Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 °C) 300 mg in one of three treatment periods |
|
| MK-0974 12Mo5C | Drug | Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 °C) 300 mg in one of three treatment periods |
|
| Through 48 hours postdose |
| D009422 | Nervous System Diseases |